NLH — Nova Leap Health Income Statement
0.000.00%
Last trade - 00:00- CA$27.50m
- CA$29.48m
- $31.47m
Annual income statement for Nova Leap Health, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 21.3 | 28.2 | 26.2 | 25.8 | 31.5 |
| Cost of Revenue | |||||
| Gross Profit | 7.21 | 9.98 | 9.77 | 9.89 | 12.5 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 18.3 | 30 | 27 | 25.1 | 30.5 |
| Operating Profit | 2.97 | -1.83 | -0.795 | 0.636 | 0.982 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 2.47 | -1.21 | -1.37 | 1.81 | -0.132 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1.76 | -0.836 | -1.05 | 1.38 | -0.19 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 1.76 | -0.836 | -1.05 | 1.38 | -0.19 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 1.76 | -0.836 | -1.05 | 1.38 | -0.19 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.012 | -0.004 | -0.003 | 0.018 | -0.001 |